Immunotherapy in Malignant Pleural Mesothelioma.

Area of Science:

• Oncology
• Immunotherapy
• Malignant Pleural Mesothelioma Research

Background:

• Current standard treatment for malignant pleural mesothelioma (MPM) is platinum-based chemotherapy with pemetrexed, +/- bevacizumab.
• Immunotherapy has shown preliminary activity in small phase II trials for MPM.
• This review focuses on immunotherapy research and future directions in MPM treatment.

Purpose of the Study:

• To review key immunotherapy research in malignant pleural mesothelioma (MPM).
• To discuss the future potential of immunotherapy in MPM treatment.
• To highlight the need for biomarkers to guide immunotherapy selection.

Main Methods:

• Review of phase II and randomized clinical trials involving immunotherapy agents.
• Analysis of response rates, progression-free survival (PFS), and overall survival (OS) data.
• Examination of combination therapies and novel immunotherapies like Dendritic Cell (DC) immunotherapy.

Main Results:

• PD-(L)1 inhibitors demonstrate response rates of 10-29% in phase II trials, with variable PFS and OS.
• Single-agent pembrolizumab did not outperform chemotherapy in pre-treated MPM patients (PROMISE-Meso trial).
• CTLA-4 inhibitors showed limited efficacy compared to best supportive care; combination PD-(L)1 and CTLA-4 inhibitors had similar responses to PD-(L)1 monotherapy. Early results of durvalumab plus chemotherapy are promising. Dendritic Cell (DC) immunotherapy shows notable anti-tumor activity.

Conclusions:

• The efficacy of single-agent checkpoint inhibitors in MPM is limited.
• Combination immunotherapies and novel approaches like DC immunotherapy warrant further investigation.
• Urgent need for biomarkers to identify optimal candidates for immunotherapy in MPM for improved efficacy and tolerance.